Drugs / Aflibercept
Aflibercept
Drug FDA approvedMarketed as Eylea
Antineovascularization agent·First approved·2011·1 brand
- Registered trials
- 174
- Ongoing
- 20/ 11%
- Completed
- 102
- Indications
- 6
Approved indications by brand
| Brand | Indication |
|---|---|
| Eylea | Neovascular (wet) age-related macular degeneration |
| Macular edema following retinal vein occlusion | |
| Diabetic macular edema | |
| Diabetic retinopathy | |
| Retinopathy of prematurity | |
| Metastatic colorectal cancer (with FOLFIRI as Zaltrap) |
Clinical trial landscape
174 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 2 | 48 | 3 | 30 | |
| Phase 3 | 44 | 11 | 25 | |
| Phase 4 | 35 | 1 | 22 | |
| Unknown | 13 | 2 | 8 | |
| Phase 1 | 10 | 0 | 7 | |
| Not applicable | 9 | 1 | 4 | |
| Phase 1/2 | 8 | 0 | 4 | |
| Phase 2/3 | 6 | 2 | 1 | |
| Early Phase 1 | 1 | 0 | 1 | |
| All phases | 174 | 20 | 102 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
Acts as a VEGF trap by binding circulating VEGF ligands and reducing angiogenesis.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.